Dare Bioscience (DARE) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dare Bioscience (DARE) has outperformed Palatin Technologies (PTN) over the past year, losing 75.8% versus a loss of 79.9%. Over five years, DARE leads with a -98.1% price change compared with -99.3% for PTN. Palatin Technologies is the larger company by market cap ($8.2 million vs $8.0 million), about 1.0 times the size.
Palatin Technologies converts more of its revenue into profit, with a net margin of -94.9% versus -1300.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DARE | PTN |
|---|---|---|
| Share price | $0.4074 | $4.58 |
| Market cap | $8.01M | $8.16M |
| 1-day change | -9.87% | -7.10% |
| YTD return | -78.89% | -70.22% |
| 1-year return | -75.75% | -79.93% |
| 5-year return | -98.10% | -99.35% |
| EPS (TTM) | $-0.61 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03M | $8.83M |
| Revenue growth (YoY) | +10429.36% | — |
| Net income (latest FY) | $-13.40M | $-8.38M |
| Gross margin | 71.29% | — |
| Operating margin | -1315.51% | -98.17% |
| Net margin | -1300.66% | -94.88% |
| 52-week high | $3.78 | $31.00 |
| 52-week low | $0.406 | $4.51 |
| Distance from 52-week high | -89.22% | -85.23% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1944.67% | +1068.12% |
| Average volume | 242.39K | 71.93K |
| Shares outstanding | 19.67M | 1.78M |
| Employees | 21 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Palatin Technologies is more profitable, keeping -94.9 cents of every revenue dollar as net income versus -1300.7 cents for Dare Bioscience.
About Dare Bioscience
DARE stock →Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
DARE vs PTN FAQ
Which is bigger, Dare Bioscience or Palatin Technologies?
Palatin Technologies (PTN) is larger, with a market capitalization of $8.16M compared with $8.01M for Dare Bioscience (DARE).
Which stock has performed better over the past year, DARE or PTN?
DARE returned -75.75% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.
Are Dare Bioscience and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.